Evidence map›Paper›PMID 25586904›Full record

ArticleCancer prevention research (Philadelphia, Pa.)2015

Involvement of epigenetics and EMT-related miRNA in arsenic-induced neoplastic transformation and their potential clinical use.

Christina Michailidi, Masamichi Hayashi, Sayantan Datta, Tanusree Sen, Kaitlyn Zenner, Oluwadamilola Oladeru, Mariana Brait, Evgeny Izumchenko, Alexander Baras, Christopher VandenBussche and 7 more

Open access · bronzeAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer prevention research (Philadelphia, Pa.), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 55 citations in OpenAlex.

  1. Article
  2. Review
  3. miRNAs and arsenic-induced carcinogenesis.Advances in pharmacology (San Diego, Calif.) · 2023
    Review
  4. Epigenomic reprogramming in iAs-mediated carcinogenesis.Advances in pharmacology (San Diego, Calif.) · 2023
    Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Epigenetic Alterations in Bladder Cancer.Current urology reports · 2018
    Review
  16. Arsenic-Induced Carcinogenesis: The Impact of miRNA Dysregulation.Toxicological sciences : an official journal of the Society of Toxicology · 2018
    Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 2 institutions in 1 country.

Christina MichailidiDepartment of Otolaryngology-Head and Neck Surgery, Johns Hopkins School of Medicine, Johns Hopkins University, Baltimore, Maryland.
Masamichi HayashiDepartment of Otolaryngology-Head and Neck Surgery, Johns Hopkins School of Medicine, Johns Hopkins University, Baltimore, Maryland.
Sayantan DattaDepartment of Otolaryngology-Head and Neck Surgery, Johns Hopkins School of Medicine, Johns Hopkins University, Baltimore, Maryland.
Tanusree SenDepartment of Otolaryngology-Head and Neck Surgery, Johns Hopkins School of Medicine, Johns Hopkins University, Baltimore, Maryland.
Kaitlyn ZennerDepartment of Otolaryngology-Head and Neck Surgery, Johns Hopkins School of Medicine, Johns Hopkins University, Baltimore, Maryland.
Oluwadamilola OladeruDepartment of Otolaryngology-Head and Neck Surgery, Johns Hopkins School of Medicine, Johns Hopkins University, Baltimore, Maryland.
Mariana BraitDepartment of Otolaryngology-Head and Neck Surgery, Johns Hopkins School of Medicine, Johns Hopkins University, Baltimore, Maryland.
Evgeny IzumchenkoDepartment of Otolaryngology-Head and Neck Surgery, Johns Hopkins School of Medicine, Johns Hopkins University, Baltimore, Maryland.
Alexander BarasDepartment of Pathology, Johns Hopkins University, Baltimore, Maryland.
Christopher VandenBusscheDepartment of Pathology, Johns Hopkins University, Baltimore, Maryland.
Maria ArgosDepartment of Health Studies, The University of Chicago, Chicago, Illinois.
Trinity J BivalacquaDepartment of Urology, Johns Hopkins University, Baltimore, Maryland.
Habibul AhsanDepartment of Health Studies, The University of Chicago, Chicago, Illinois. Departments of Medicine and Human Genetics and Comprehensive Cancer Center, The University of Chicago, Chicago, Illinois.
Noah M HahnDepartment of Oncology, Johns Hopkins University, Baltimore, Maryland.
George J NettoDepartment of Pathology, Johns Hopkins University, Baltimore, Maryland. Department of Urology, Johns Hopkins University, Baltimore, Maryland.
David SidranskyDepartment of Otolaryngology-Head and Neck Surgery, Johns Hopkins School of Medicine, Johns Hopkins University, Baltimore, Maryland.
Mohammad Obaidul HoqueDepartment of Otolaryngology-Head and Neck Surgery, Johns Hopkins School of Medicine, Johns Hopkins University, Baltimore, Maryland. Department of Urology, Johns Hopkins University, Baltimore, Maryland. Department of Oncology, Johns Hopkins University, Baltimore, Maryland. mhoque1@jhmi.edu.
Johns Hopkins University · USChicago Department of Public Health · US

Funding

Treatment of HIV- and HIV+ Patients with HPV16+ CIN2/3 Using pNGLV4a-hCRTE6E7L2 DNA vaccine administered intramuscularly via electroporationP50CA098252 · NCI · JOHNS HOPKINS UNIVERSITY · PI TZYY-CHOOU WU · 2003 to 2026
$53.5M
Re-Engineering Translational Research at the University of ChicagoUL1TR000430 · NCATS · UNIVERSITY OF CHICAGO · PI SOLWAY, JULIAN · 2012 to 2016
$20.2M
Discovery and Characterization of Methylation MarkersR01CA163594 · NCI · JOHNS HOPKINS UNIVERSITY · PI SIDRANSKY, DAVID · 2012 to 2016
$1.8M
Summer Translational Oncology Program (STOP)R25CA171973 · NCI · JOHNS HOPKINS UNIVERSITY · PI BUNZ, FRED, EMENS, LEISHA A · 2013 to 2017
$340k
NCATS NIH HHS UL1 TR000430NCI NIH HHS P50 CA098252NCI NIH HHS R01 CA163594NCI NIH HHS R01CA163594NCI NIH HHS R25 CA171973
6 · The paper itself

Abstract

Exposure to toxicants leads to cumulative molecular changes that overtime increase a subject's risk of developing urothelial carcinoma. To assess the impact of arsenic exposure at a time progressive manner, we developed and characterized a cell culture model and tested a panel of miRNAs in urine samples from arsenic-exposed subjects, urothelial carcinoma patients, and controls. To prepare an in vitro model, we chronically exposed an immortalized normal human bladder cell line (HUC1) to arsenic. Growth of the HUC1 cells was increased in a time-dependent manner after arsenic treatment and cellular morphology was changed. In a soft agar assay, colonies were observed only in arsenic-treated cells, and the number of colonies gradually increased with longer periods of treatment. Similarly, invaded cells in an invasion assay were observed only in arsenic-treated cells. Withdrawal of arsenic treatment for 2.5 months did not reverse the tumorigenic properties of arsenic-treated cells. Western blot analysis demonstrated decreased PTEN and increased AKT and mTOR in arsenic-treated HUC1 cells. Levels of miR-200a, miR-200b, and miR-200c were downregulated in arsenic-exposed HUC1 cells by quantitative RT-PCR. Furthermore, in human urine, miR-200c and miR-205 were inversely associated with arsenic exposure (P = 0.005 and 0.009, respectively). Expression of miR-205 discriminated cancer cases from controls with high sensitivity and specificity (AUC = 0.845). Our study suggests that exposure to arsenic rapidly induces a multifaceted dedifferentiation program and miR-205 has potential to be used as a marker of arsenic exposure as well as a maker of early urothelial carcinoma detection.

Indexed as

Epithelial-Mesenchymal TransitionAdultAgedAged, 80 and overApoptosisArsenicBiomarkers, TumorBlotting, WesternCase-Control StudiesCell MovementCell ProliferationCells, CulturedCell Transformation, NeoplasticCohort StudiesDNA MethylationEpigenesis, GeneticArsenicBiomarkers, TumorMicroRNAsMTOR protein, humanPTEN PhosphohydrolasePTEN protein, humanRNA, MessengerTOR Serine-Threonine Kinases

Identifiers

PMID25586904
PMCPMC4355280
OpenAlexW2124254631

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.